Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The study is designed with drugs used frequently in the treatment of AML, but with a new
combination less toxic,and effective in AML multidrug resistant.
Justification:
- The AML patients with primary resistance or relapsed in the first 12 months after CR,
have second line chemotherapy low response rate .
- These patients with AML with primary resistance or relapse, that reach remission after a
rescue treatment, have an interval free survival and a global survival very short
- Probably the resistance to the treatments is in relation to different forms expression
of the MDR.
- Complete remission is considered valid evaluation, because every patient who should
obtain a CR can be considered to be eligible for a possible curative treatment: Ara-C
administration to high doses or the TPH treatment